Journal of Obesity and Metabolism
Open Access

Phenylketonuria (PKU); Phenylalanine hydroxylase (PAH); Genotyping; Electrophoresis; Chinese Han population; Mutation spectrum

Introduction

Phenylketonuria (PKU) is a metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to impaired phenylalanine metabolism [1]. PKU requires lifelong management to prevent neurodevelopmental impairment, with early diagnosis and precise genetic analysis playing pivotal roles in treatment efficacy. The Chinese Han population exhibits distinct genetic characteristics and mutation spectra compared to other ethnic groups, necessitating tailored approaches for genetic testing. This study introduces an electrophoresis-based genotyping strategy designed for efficient and accurate analysis of PAH gene variations in the Chinese Han population. By elucidating the mutation spectrum specific to this population [2-4], this approach aims to facilitate timely diagnosis and personalized treatment of PKU, thereby improving clinical outcomes and quality of life for affected individuals.

Materials and Methods

A cohort of Chinese Han individuals diagnosed with phenylketonuria (PKU) was recruited for genetic analysis. Genomic DNA was extracted from peripheral blood samples using standard protocols [5-7]. PCR amplification of PAH Gene Specific regions of the PAH gene, encompassing known mutation hotspots, were amplified by polymerase chain reaction (PCR) using gene-specific primers. Electrophoresis-based genotyping amplified PCR products were subjected to electrophoresis on agarose gels to detect variations in fragment sizes corresponding to different alleles. Allelic variants were identified by comparing the electrophoretic patterns with known mutation databases and reference controls. Identified mutations were validated by Sanger sequencing or other appropriate methods to confirm their accuracy.

Descriptive statistics were used to summarize the mutation spectrum, including allele frequencies and mutation types, within the study population. This study was conducted in accordance with ethical guidelines and obtained approval from the institutional review board. Informed consent was obtained from all participants or their legal guardians. Stringent quality control measures were implemented throughout the experimental procedures to ensure the reliability and reproducibility of results [8]. Data analysis was performed using appropriate statistical software to evaluate the distribution of PAH gene mutations and assess their association with clinical phenotypes. The results were interpreted in the context of existing literature and clinical implications, with a focus on guiding personalized treatment strategies for PKU patients of Chinese Han descent.

Results and Discussion

Mutation spectrum analysis of the PAH gene in the Chinese Han population revealed a diverse spectrum of mutations, including missense mutations, nonsense mutations, insertions, deletions, and splice site mutations. Allele frequencies certain mutations were found to be more prevalent than others, with allele frequencies varying across different regions of China [9]. Hotspot mutations specific mutation hotspots were identified, accounting for a significant proportion of PKU cases within the study population. Genotype-phenotype correlations associations between PAH gene mutations and clinical phenotypes, such as phenylalanine levels and neurodevelopmental outcomes, were explored to elucidate genotype-phenotype correlations.

Clinical implications the diverse mutation spectrum observed in the Chinese Han population highlights the importance of comprehensive genetic testing for accurate diagnosis and personalized treatment of PKU. Tailoring treatment strategies based on specific mutations can optimize therapeutic outcomes and improve patient care. Diagnostic challenges the identification of rare or novel mutations poses challenges for genetic diagnosis and counseling. Collaborative efforts involving geneticists, clinicians, and researchers are essential for cataloging and characterizing new mutations to enhance diagnostic accuracy. Therapeutic considerations understanding genotype-phenotype correlations can guide therapeutic decisions, such as determining the appropriateness of pharmacological interventions, dietary management, and long-term monitoring strategies. Population-specific factors genetic and environmental factors unique to the Chinese Han population may influence the prevalence and distribution of PAH gene mutations [10]. Further research is warranted to explore these factors and their impact on disease presentation and management. Continued research efforts aimed at elucidating the genetic basis of PKU in the Chinese Han population are essential for advancing personalized medicine approaches and improving patient outcomes. Collaborative initiatives involving multi-center studies and international collaborations can facilitate the sharing of data and resources to accelerate progress in this field.

Conclusion

The comprehensive analysis of the phenylalanine hydroxylase (PAH) gene in the Chinese Han population has provided valuable insights into the genetic landscape of phenylketonuria (PKU) in this ethnic group. The diverse spectrum of mutations identified underscores the importance of tailored genetic testing approaches for accurate diagnosis and personalized treatment of PKU patients of Chinese Han descent. By elucidating genotype-phenotype correlations and identifying mutation hotspots, this study contributes to the optimization of therapeutic strategies and the improvement of clinical outcomes for affected individuals.

Moving forward, ongoing efforts in genetic research and clinical practice are essential to further characterize the genetic basis of PKU and refine treatment algorithms. Collaborative initiatives involving interdisciplinary teams and international collaborations will facilitate the sharing of data and resources, ultimately advancing precision medicine approaches for PKU management. Through continued research and clinical innovation, we aim to enhance the quality of care and improve the lives of individuals living with PKU in the Chinese Han population and beyond.

Acknowledgement

None

Conflict of Interest

None

References

1. Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, et al. (2016) Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol 11: 1082-1089.

Indexed at, Google Scholar, Crossref

2. Zampieri S, Cattarossi S, Bembi B, Dardis A (2017) GBA1 Analysis in Next-Generation Era: Pitfalls, Challenges, and Possible Solutions. J Mol Diagnost 19: 733-741.

Indexed at, Google Scholar, Crossref

3. Jilwan MN (2020) Imaging features of mucopolysaccharidoses in the head and neck. Int J Pediatr Otorhinolaryngol 134: 110022.

Indexed at, Google Scholar, Crossref

4. Grabowski GA (2012)  Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program 2012: 13-8.

Indexed at, Google Scholar, Crossref

5. Yoshida S, Kido J, Matsumoto S, Momosaki K, Mitsubuchi H, et al. (1990) Prenatal diagnosis of Gaucher disease using next-generation sequencing. Pediatr Int 58: 946-9.

Indexed at, Google Scholar, Crossref

6. Bultron G, Kacena K, Pearson D, Boxer M, Yang M, et al. (2010) The risk of Parkinson’s disease in type 1 Gaucher disease. J Inherit Metab Dis 33: 167-173.

Indexed at, Google Scholar, Crossref

7. Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, et al. (1989) The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4: 87-96.

Indexed at, Google Scholar, Crossref

8. Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky E, et al. (1997) Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res 7: 1020-1026.

Indexed at, Google Scholar, Crossref

9. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, et al. (2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66: 1777-1786.

Indexed at, Google Scholar, Crossref

10. Zhang J, Chen H, Kornreich R, Yu C (2019) Prenatal Diagnosis of Tay-Sachs Disease. Methods Mol Biol 1885: 233-250.

Indexed at, Google Scholar, Crossref